Abstract
Introduction Syndromic management is widely used to treat symptomatic sexually transmitted infections in settings lacking aetiologic diagnostics. However, heterogeneity in underlying aetiologies and consequent treatment suitability are uncertain without regular assessment. This systematic review characterised aetiologies for vaginal discharge, urethral discharge, and genital ulcer in sub-Saharan Africa (SSA).
Methods We searched Embase, MEDLINE, Global Health, and Web of Science until July 25, 2022, and grey literature until August 31, 2022, for studies reporting aetiologic diagnoses among symptomatic populations in SSA. We adjusted observations for diagnostic test performance and used generalised linear mixed-effects meta-regressions to estimate aetiologic distributions, trends, and determinants.
Results Of 4136 identified records, 198 reports were included from 183 studies in 32 countries between 1969 and 2022. In 2015, primary aetiologies for vaginal discharge were candidiasis (69.4% [95% CI:44.1-86.6%], n=50), bacterial vaginosis (50.0% [32.3-67.8%], n=39), chlamydia (16.5% [8.7-29.0%], n=49), and trichomoniasis (12.9% [7.7-20.7%], n=78); for urethral discharge were gonorrhoea (78.8% [70.9-85.1%], n=67) and chlamydia (22.2% [16.0-30.1%], n=48); and for genital ulcer were HSV-2 (56.1% [39.2-71.6%], n=46) and syphilis (7.8% [5.3-11.4%], n=115). Regional variation was marginal. Temporal variation was substantial, particularly for genital ulcer. For each symptom, HIV-status and age were significantly associated with infection diagnoses, although aetiologic hierarchies were largely the same by strata.
Conclusion Syndrome aetiologies in SSA align with WHO guidelines without strong evidence of contextual or demographic variation, supporting broad guideline applicability. Temporal changes underscore the need for aetiologic re-assessment. STI surveillance using syndrome-based assessments is noncomprehensive and requires studies among symptomatic and asymptomatic populations.
PROSPERO number CRD42022348045
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JM acknowledges funding from the Imperial College President's PhD Fund. JWI-E acknowledges funding from the Bill & Melinda Gates Foundation (INV-006733, INV-002606). JM, MKW, OE, AC, M-CB, and JWI-E acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the Imperial College Research Ethics Committee (ICREC #6389606)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract
Data Availability
All data produced in the present work are contained in the supplementary materials.
